Frank Dolan

Unlocking Global Biotech Growth: Navigating Complexity

Frank Dolan April 30, 2024

Fortifying Biotech’s Lifeline: Mastering Supply Chain Risks

Frank Dolan April 30, 2024

Navigating the Fast Lane of Drug Approval

Frank Dolan April 30, 2024

Big Pharma’s Acquisition Spree: Opportunity Amidst Challenges

Frank Dolan April 30, 2024

A team of pediatric neurologists happily unveiling Libervant medication to a group of children aged 2 to 5, with a background of cheerful parents and a banner that reads 'FDA Approved for Seizure Clusters Treatment'

FDA Grants Approval to Aquestive Therapeutics’ Libervant for Managing Seizure Clusters in Toddlers Aged 2-5 Years.

Frank Dolan April 29, 2024

Detailed digital illustration of Coya Therapeutics CEO confidently discussing innovative treatment pipeline with a futuristic, high-tech lab background, showcasing various stages of drug development and research.

CEO of Coya Therapeutics Talks About the Firm’s Range of Treatments.

Frank Dolan April 26, 2024

An illustrated scene of scientists from Novartis and Medicines for Malaria Venture celebrating in a laboratory, surrounded by images of the Coartem medication and a smiling infant symbolizing recovery from malaria.

Novartis and Medicines for Malaria Venture Announce Favorable Outcomes from Phase II/III Study of Coartem in Treating Malaria in Infants

Frank Dolan April 25, 2024

An illustration of a confident CEO presenting the promising results of the Coya 302 trial for ALS treatment to an audience of medical professionals and researchers, with a backdrop of futuristic biotechnology labs and hopeful ALS patients watching.

Coya Therapeutics Chief Executive Talks Future Plans Following Encouraging Outcomes from ALS Therapy Trial Coya 302.

Frank Dolan April 24, 2024

A team of pediatric doctors joyfully presenting a vial of Lutathera under a spotlight, with a background of animated gastroenteropancreatic neuroendocrine tumors turning into stars, symbolizing hope and healing for pediatric patients.

FDA Grants Approval to Novartis’ Lutathera for Children with Gastroenteropancreatic Neuroendocrine Cancers

Frank Dolan April 23, 2024

Digital artwork illustrating a modern, diverse pharmaceutical sales and marketing team strategizing over virtual and augmented reality tools, with global market data floating in the air around them.

Present Condition of the Pharmaceutical Sales and Marketing Workforce.

Frank Dolan April 22, 2024

Scientists in a high-tech laboratory wearing protective equipment and working together to develop a bird flu vaccine, with a detailed illustration of the H5N1 virus structure in the background and a Texas flag subtly incorporated.

Texas Biomed Working on Potential Vaccine for Bird Flu.

Frank Dolan April 19, 2024

An artist's interpretation of a futuristic medical laboratory highlighting the successful Phase III SELECT-GCA trial for Rinvoq, with scientists examining glowing test tubes and digital screens displaying giant cell arteritis data.

Promising Outcomes from Phase III SELECT-GCA Study of Rinvoq in Treating Giant Cell Arteritis Patients.

Frank Dolan April 18, 2024

An intricate digital illustration visualizing a maze made of swirling financial documents, tax forms, and calculators, with a navigational compass overlaid, highlighting the complexities of the IRA landscape.

Understanding the Changing Complexities of the IRA: A Guide.

Frank Dolan April 16, 2024

Digital art of a handshake between two corporate figures, with symbols of Novartis and Arvinas logos in the background, overlaying a futuristic laboratory working on prostate cancer treatment.

Novartis and Arvinas Enter Strategic Partnership to Advance Prostate Cancer Treatment Development.

Frank Dolan April 12, 2024

An illustration of a medical professional demonstrating diverse methods of administering SK Life Science's Xcorpi to adults suffering from partial-onset seizures, in a bright, modern clinic setting.

FDA Green-lights Novel Delivery Approaches for SK Life Science’s Xcorpi in Treating Adults with Partial-Onset Seizures.

Frank Dolan April 11, 2024

An illustration of two scientists in lab coats shaking hands in front of a large, futuristic laboratory, with a 3D model of a bispecific antibody floating between them, symbolizing the partnership between Invenra and Astellas.

Invenra and Astellas Initiate Collaboration Aimed at Identifying Bispecific Antibody Treatments.

Frank Dolan April 10, 2024

Digital illustration depicting Lonza and NeuroSense collaborating in a futuristic laboratory, surrounded by glowing biological markers and advanced equipment, exploring solutions for neurodegenerative diseases.

NeuroSense Partners with Lonza to Investigate Biomarkers in Neurodegenerative Conditions.

Frank Dolan April 9, 2024

FDA Sanctions Broadened Usage of Dovato for Adolescent HIV Patients

Frank Dolan April 8, 2024

An illustration of two giant puzzle pieces fitting together, one labeled 'Johnson & Johnson' and the other 'Shockwave Medical', against a backdrop of high-tech medical equipment and heart health symbols, highlighting collaboration and growth in the medical technology industry.

Johnson & Johnson Plans to Purchase Shockwave Medical to Bolster Its MedTech Unit

Frank Dolan April 5, 2024

A scientist excitedly revealing a graph with positive data from Moderna's mRNA-3927 Phase I/II clinical trial for Propionic Acidemia, in a modern research laboratory setting.

Moderna Unveils Encouraging Results from Early-Stage Clinical Study on mRNA-3927 for Treating Propionic Acidemia

Frank Dolan April 4, 2024

Stay up to date on the latest news

By pressing the Subscribe button, you confirm that you have read our Privacy Policy.

Iovance Biotherapeutics Stock Plummets 44%: What Investors Need to Know About 2025 Projections

Insilico Medicine’s Third Attempt at an IPO: Aiming Big in Hong Kong’s Booming Biotech Market

Biotech Sector Faces Major Workforce Cuts: Layoffs Surge as Firms Navigate Market Turbulence

Email Us

info at arsenal-advisors.com

Headquarters

Cambridge, MA USA

Frank Dolan

Unlocking Global Biotech Growth: Navigating Complexity

Fortifying Biotech’s Lifeline: Mastering Supply Chain Risks

Navigating the Fast Lane of Drug Approval

Big Pharma’s Acquisition Spree: Opportunity Amidst Challenges

FDA Grants Approval to Aquestive Therapeutics’ Libervant for Managing Seizure Clusters in Toddlers Aged 2-5 Years.

CEO of Coya Therapeutics Talks About the Firm’s Range of Treatments.

Novartis and Medicines for Malaria Venture Announce Favorable Outcomes from Phase II/III Study of Coartem in Treating Malaria in Infants

Coya Therapeutics Chief Executive Talks Future Plans Following Encouraging Outcomes from ALS Therapy Trial Coya 302.

FDA Grants Approval to Novartis’ Lutathera for Children with Gastroenteropancreatic Neuroendocrine Cancers

Present Condition of the Pharmaceutical Sales and Marketing Workforce.

Texas Biomed Working on Potential Vaccine for Bird Flu.

Promising Outcomes from Phase III SELECT-GCA Study of Rinvoq in Treating Giant Cell Arteritis Patients.

Understanding the Changing Complexities of the IRA: A Guide.

Novartis and Arvinas Enter Strategic Partnership to Advance Prostate Cancer Treatment Development.

FDA Green-lights Novel Delivery Approaches for SK Life Science’s Xcorpi in Treating Adults with Partial-Onset Seizures.

Invenra and Astellas Initiate Collaboration Aimed at Identifying Bispecific Antibody Treatments.

NeuroSense Partners with Lonza to Investigate Biomarkers in Neurodegenerative Conditions.

FDA Sanctions Broadened Usage of Dovato for Adolescent HIV Patients

Johnson & Johnson Plans to Purchase Shockwave Medical to Bolster Its MedTech Unit

Moderna Unveils Encouraging Results from Early-Stage Clinical Study on mRNA-3927 for Treating Propionic Acidemia

Stay up to date on the latest news

Access the Ideas that Accelerate Innovation

Trending News

Iovance Biotherapeutics Stock Plummets 44%: What Investors Need to Know About 2025 Projections

Insilico Medicine’s Third Attempt at an IPO: Aiming Big in Hong Kong’s Booming Biotech Market

Biotech Sector Faces Major Workforce Cuts: Layoffs Surge as Firms Navigate Market Turbulence

Popular Categories

Information

Contact Us